Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs DexCom, Inc. (DXCM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs DexCom, Inc. — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $1.88 (market cap $1.69B), while DexCom, Inc. trades at $74.97 (market cap $28.93B). The key difference: DexCom, Inc. is far larger — about 17.1× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| AMC | DXCM | |
|---|---|---|
Market Cap | $1.69B | $28.93B |
Sector | Media | Health |
52-Week High | $3.54 | $89.53 |
52-Week Low | $0.95 | $54.84 |
Enterprise Value | $9.28B | $27.89B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $1.89, down 0.53% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of -$0.36, missing expectations, while revenue trends show modest growth from $4.6B in 2024 to $4.85B in 2025. Recent news highlights box office recovery optimism and a $200 million stock offering that caused dilution concerns.
Outlook remains challenging with persistent net losses and high debt burden, though analyst consensus targets $1.90 with 32% buy ratings. Key risks include ongoing dilution from equity offerings, competitive pressures in entertainment, and the need for sustained box office recovery to improve cash flow and profitability.
DXCM trades at $74.96, up 2.66% today, with strong technical momentum as price approaches resistance near $76. The company demonstrates robust fundamentals with revenue growth from $2.9B in 2022 to $4.7B in 2025 and expanding net margins to 17.93%. Recent FDA clearance for pediatric Stelo CGM and positive CONNECT trial results support growth in the non-insulin diabetes market.
Outlook remains positive with 80% analyst buy ratings and $83.78 consensus target, though risks include GLP-1 drug competition and execution in expanding beyond insulin-dependent patients. Earnings beat expectations in three consecutive quarters, with Q2 2026 results anticipated July 30, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
